THE USE OF PROSTADOZ IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND COEXISTENT HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA
- Authors: Antonov A.G1,2, Gordeev V.V1,3, Fedorchuk S.B4, Laptev D.O5
-
Affiliations:
- Far Eastern State Medical University of Minzdrav of Russia
- City Clinical Hospital No. 10, Minzdrav of Khabarovsk Krai
- Clinical Hospital at Khabarovsk Station-1 of JSC «RZD»
- Regional Clinical Oncology Center of Minzdrav of the Khabarovsk Krai
- Lekar LLC, Clinical and Diagnostic Center
- Issue: No 5 (2017)
- Pages: 58-62
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/322088
- DOI: https://doi.org/10.18565/urology.2017.5.58-62
- ID: 322088
Cite item
Open Access
Access granted
Abstract
Introduction. In recent years there has been an increasing interest in the drug treatment of benign prostatic hyperplasia (BPH) to improve the patients’ quality of life without surgical treatment. In this connection, phytotherapeutic drugs and biologically active dietary supplements (BADS), consisting of a combination of microelements, vitamins and plant extracts, have been increasingly used in addition to synthetic preparations. Objective. To investigate the clinical effectiveness of dietary supplement ProstaDoz® in the treatment of BPH with coexistent high-grade prostatic intraepithelial neoplasia (PIN). Materials and methods. The study group comprised 30 men with BPH and high-grade PIN who were diagnosed with primary biopsy and received ProstaDoz® for three months. The control group included 18 patients with the same diagnosis who were treated with Tamsulosin. Results. After a 3-month intake of the ProstaDoz®, a statistically significant reduction was observed in symptom scores for BPH and the quality of life index by 18% (p<0.001) and 16.7% (p<0.001), respectively. The residual urine volume and total serum PSA decreased by 28.3% (p<0.001) and 46.8% (p<0.001), respectively. Unlike the control group, the rate of prostate cancer detection was 6.25 times lower in patients taking ProstaDoz®, and 16% of them had lower grade PIN compared with baseline or no PIN at all. Conclusion. The findings suggest that using ProstaDoz® in patients with BPH and high-grade PIN contributes to improving the quality of life (QoL) of patients and the regression of dysplasia.
Full Text
About the authors
A. G Antonov
Far Eastern State Medical University of Minzdrav of Russia; City Clinical Hospital No. 10, Minzdrav of Khabarovsk Krai
Email: antonovs@rambler.ru
Dr.Med.Sci., Professor, Head of the Urology Center; Head of the Department of Urology and Nephrology Khabarovsk, Russia
V. V Gordeev
Far Eastern State Medical University of Minzdrav of Russia; Clinical Hospital at Khabarovsk Station-1 of JSC «RZD»
Email: gordeevs80@gmail.com
Ph.D., Head of the Department of Urology; Associate Professor of the Department of Urology and Nephrology Khabarovsk, Russia
S. B Fedorchuk
Regional Clinical Oncology Center of Minzdrav of the Khabarovsk Krai
Email: gordeevs80@gmail.com
Urologist-oncologist Khabarovsk, Russia
D. O Laptev
Lekar LLC, Clinical and Diagnostic CenterUrologist Khabarovsk, Russia
References
- Egan K.B. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43:289.
- Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа. 2015;480 с. ISBN: 978-5-9704-312-9
- Jouvenel H. Europe’s ageing population Trends and challenges to 2025. Buttermoth. 1999.
- Петричко М.И., Волков А.А. Медикаментозная терапия больных доброкачественной гиперплазией предстательной железы - современные подходы. М.: Редакционно-издательский отдел Центра последипломного образования НУЗ «НКЦ ОАО РЖД». 2015;115 с. ISBN: 978-5-4465-0830-3
- Dоnnеll R.F. Веnign рrostatе hурегр1asiа: а review оf &е уеаЛ ргоgгеss from bench 1о clinic. Curr Орт Ure1. 2011;1:22-26.
- Пушкарь Д.Ю., Раснер П.И. Доброкачественная гиперплазия предстательной железы. Библиотека пациента. Русский медицинский журнал. Урология. 2013;8:19
- Пушкарь Д.Ю., Раснер П.И. Дифференциальная диагностика рака и доброкачественной гиперплазии предстательной железы. Русский медицинский журнал. 2014;17:1298-1303
- Coley C.M., Barry M.J., Fleming C. еt аі Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann. Intern. Med. 1997;126(5):394-406.
- Антонов А.Г., Гордеев В.В. Простатическая интраэпителиальная неоплазия высокой степени как тканевый маркер выявления рака предстательной железы. Дальневосточный медицинский журнал. 2008;2:49-51
- Асаад О., Мешков В.В. Урологические осложнения рака предстательной железы. Международный Медицинский журнал. 2002;4:23
- Bostwick, D.G., Brawer M.K. Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer. 1987;59:788-794.
- Сивков А.В., Кудрявцев Ю.В., Медведев А.А. и др. Морфологические изменения в ткани предстательной железы больных с доброкачественной гиперплазией предстательной железы при лечении пермиксоном. Урология. 2004;5:10-15
- Аляев Ю.Г., Рапопорт Л.М., Цариченко Д.Г., Ганжа Т.М., Крупинов Г.Е. Простадоз - возможность привентивной терапии рака простаты. Урология. 2015;6:58-66
- Brausi M., Rizzi F., Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur. Urol. 2008;54(2):472-473.
Supplementary files
